TAK
HEALTHCARETakeda Pharmaceutical Company
$16.72+0.17 (+1.03%)LIVE
Live · NYSE · May 9, Close
AI Insight
What's Moving TAK Today?
No stock-specific AI insight has been generated for TAK yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$12.78$18.90
$16.72
Fundamentals
Market Cap$52.8B
P/E Ratio76.0
EPS$0.22
Dividend Yield0.04%
Dividend / Share$198.00
ROE0.0%
Profit Margin0.0%
Debt / Equity—
Trading
Volume3.4M
Avg Volume (10D)—
Shares Outstanding3.16B
TAK News
26 articles- DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts ProspectsYahoo Finance·May 8, 2026
- Timothy P. Walbert Joins Patient Square Capital as a Senior AdvisorYahoo Finance·May 6, 2026
- Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·May 5, 2026
- Will the Label Expansion of Asceniv Boost ADMA's Top-Line Growth?Yahoo Finance·May 5, 2026
- Model N Appoints Thomas Gibbs to Board of DirectorsYahoo Finance·May 5, 2026
- Zifo's SiEE Boston Summit Charts New Roadmap for 'Practical AI' in Life Sciences, Bridging the Gap Between Business Vision and Lab RealityYahoo Finance·May 5, 2026
- British Columbia reimburses REVESTIVE® (teduglutide for injection) for the treatment of Short Bowel SyndromeYahoo Finance·May 5, 2026
- Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)Yahoo Finance·May 4, 2026
- Why Denali Therapeutics (DNLI) Is Down 8.2% After Takeda Exits DNL593 Collaboration And Returns RightsYahoo Finance·May 4, 2026
- Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Japanese Stocks Amid Restructuring Drive?Yahoo Finance·May 2, 2026
- Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?Yahoo Finance·Apr 30, 2026
- AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's DiseaseYahoo Finance·Apr 30, 2026
- IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsightGlobeNewswire Inc.·Apr 29, 2026
- What Makes Denali Therapeutics (DNLI) One of the Best Biotech Stocks to Invest inYahoo Finance·Apr 29, 2026
- HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB ConferenceMarketbeat·Apr 29, 2026
- Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda CollaborationYahoo Finance·Apr 28, 2026
- Pancreatic Neuroendocrine Tumors Market Research Report 2025-2035, Competitive Analysis of Key Players - Novartis, Pfizer, Exelixis, Merck, Ipsen Pharma, and Takeda PharmaYahoo Finance·Apr 28, 2026
- Intellia Successfully Edited Genes Inside The Body. Why Shares Aren't Flying.Yahoo Finance·Apr 27, 2026
- ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?Yahoo Finance·Apr 24, 2026
- Germany Anemia Treatment Market Forecast and Company Analysis Report 2026-2034 Featuring Akebia Therapeutics, GSK, Vertex, Pfizer, Sanofi, Takeda, Novartis, Johnson & Johnson, Roche, Biocon BiologicsYahoo Finance·Apr 24, 2026
- Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsightGlobeNewswire Inc.·Apr 22, 2026
- Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsightGlobeNewswire Inc.·Apr 16, 2026
- The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsightGlobeNewswire Inc.·Apr 14, 2026
- Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsightGlobeNewswire Inc.·Apr 13, 2026
- Crohn's Disease Eight-Market Drug Forecast and Market Analysis Report 2025-2026: Novel MOAs Will Provide Market Shifts Throughout the Forecast Period to 2032GlobeNewswire Inc.·Apr 10, 2026
- Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's WhyBenzinga·Apr 6, 2026
All 26 articles loaded
Price Data
Open$16.73
Previous Close$16.55
Day High$16.80
Day Low$16.60
52 Week High$18.90
52 Week Low$12.78
52-Week Range
$12.78$18.90
$16.72
Fundamentals
Market Cap$52.8B
P/E Ratio76.0
EPS$0.22
Dividend Yield0.04%
Dividend / Share$198.00
ROE0.0%
Profit Margin0.0%
Debt / Equity—
Trading
Volume3.4M
Avg Volume (10D)—
Shares Outstanding3.16B
About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeStock
ExchangeNYSE
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—